Comprehensive panels Leverage Eurofins Diatherix's wide range of multiplex panels (respiratory, GI, UTI, wound, STI) to position cross-selling opportunities for clinics and hospitals seeking one-stop molecular diagnostics with rapid, accurate results.

Proprietary technology Highlight the unique TEM PCR technology as a differentiator that delivers high specificity and sensitivity across multiple pathogens, enabling higher confidence in results and potential premium pricing or faster payer approvals.

Antibiotic stewardship Emphasize the UTI panel and resistance gene detection to support antimicrobial stewardship programs, appealing to health systems aiming to optimize antibiotic use and meet regulatory or accreditation requirements.

Rapid expansion signals Note past lab expansions and US COVID-19 testing deployment as indicators of capability and scalability, suggesting readiness to scale partnerships with health networks, academic centers, and large clinics.

Strategic partnerships Target collaboration opportunities with hospitals, ID physicians, and public health entities by offering bundled molecular diagnostics, rapid turnaround, and comprehensive pathogen coverage to improve patient outcomes and reduce hospital stays.